Why are CSL shares falling today?

CSL shareholders may have mixed feelings today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is down 2% in early trading as the ASX healthcare share feels the effects of the ASX stock market sell-off. CSL shares also went ex-dividend today.

On Friday in the US market, there was a sizeable decline in a number of stocks. Nvidia fell 5.5%, Eli Lilly dropped 2.3%, Microsoft declined 0.7%, Tesla fell 1.8% and so on. The S&P/ASX 200 Index (ASX: XJO) is currently down by 1.3%.

Cropped shot of an attractive young female scientist working on her computer in the laboratory.

Image source: Getty Images

Ex-dividend day

One of the factors that may be impacting CSL shares today is that it went ex-dividend.

An ex-dividend date tells the market when new investors buying shares will miss out on the upcoming dividend. There has to be a cut-off point for deciding who will and who won't receive the dividend.

Anyone who buys today is missing out on the interim dividend payment. Investors who bought CSL shares last week are eligible to receive the dividend, assuming they're still shareholders on the record date (tomorrow).

How much is being paid?

CSL is going to pay a dividend of US$1.19 to shareholders, which at the time of the FY24 first-half result translated into approximately A$1.81 per share (an increase of 12%).

At the current exchange rates, the upcoming payment equates to A$1.80 per share.

CSL is expecting to release information about exchange rates for Australian and New Zealand dollar payments on 14 March 2024.

The ASX healthcare share is planning to pay this dividend on 3 April 2024, which is only a few weeks away.

CSL was able to deliver a bigger dividend after growing net profit after tax (NPAT) by 17% to US$1.9 billion in its FY24 first-half result. It also reported underlying earnings per share (EPS) growth of 11% to US$4.18.

Profit expectations

The company is expecting to report underlying NPATA of between US$2.9 billion to US$3 billion, which would be growth of between 13% to 17%.

Management thinks the business is in a strong position to deliver annualised double-digit earnings growth over the medium term.

On Commsec, the estimates imply the CSL share price is currently valued at 30 times FY24's estimated earnings. It could pay an annual dividend of A$4, according to Commsec, which puts the forecast forward dividend yield at 1.4%.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Microsoft, Nvidia, and Tesla. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended CSL and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech company has piled on more than 25% after a big announcement

A deal around a novel drug delivery compound has investors interested.

Read more »

A young man stands facing the camera and scratching his head with the other hand held upwards wondering if he should buy Whitehaven Coal shares
Healthcare Shares

Telix shares drop despite promising US FDA update

Market weakness is overshadowing this news.

Read more »

Stressed, unhappy and tired scientist with a headache working on a computer in a lab. Worried, anxious and frustrated pathologist, researcher and doctor struggling with burnout, tension and strain.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this ASX share deliver healthy returns or will things get worse?

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Game over? ASX biotech stock crashes 90% on big bad news

Is it game over for this stock? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Should you buy low on these ASX healthcare stocks?

These two stocks could be poised for a bounce back.

Read more »

Woman with a concerned look on her face holding a credit card and smartphone.
Healthcare Shares

What on earth's going on with the CSL share price?

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more…

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

These ASX healthcare stocks are set to thrive as the population ages

A powerful demographic tailwind, but can they execute?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This drug developer could have huge upside, brokers say

Gains of more than 100% are not off the cards apparently.

Read more »